Merz Pharmaceuticals GmbH
https://www.merz.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merz Pharmaceuticals GmbH
Ocuphire Eyes Phase III Path For APX3330 After Mixed Trial Results
The diabetic retinopathy candidate failed on its Phase II primary endpoint, but showed efficacy on a key secondary endpoint that the company hopes to use as the Phase III primary outcome measure.
Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Chinese Biotechs Raise $212m Through Major VC/PE Deals in November
Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- BioteCon Therapeutics GmbH
- Cabochon Aesthetics, Inc.
- ON Light Sciences, Inc.
- Ulthera, Inc.
- Merz Pharmaceuticals GmbH
- Merz Pharma France
- Merz North America, Inc.
- Merz Pharma (Schweiz) Ag
- Merz Pharma GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice